Nephrology
Latest news
146 articles · 20 / page
Predicting Cardiovascular Outcomes in Fabry Disease: Identifying High-Risk Markers in the Modern Therapeutic Era
A multicenter study of 680 Fabry disease patients reveals that age, renal function, QRS duration, and left ventricular mass are critical independent predictors of major adverse cardiovascular events, highlighting persistent unmet needs desp
Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum
A post hoc analysis of the CRHCP trial demonstrates that intensive blood pressure control ( **Confirming JSON Structure** I’m now fully focused on creating the JSON object. I’ve re-reviewed both schemas, and am following the most up-to-date
Sibeprenlimab Achieves 51% Reduction in Proteinuria for IgA Nephropathy: Key Interim Insights from the Phase 3 VISIONARY Trial
The Phase 3 VISIONARY trial interim analysis demonstrates that sibeprenlimab, a monoclonal antibody targeting APRIL, significantly reduces proteinuria and pathogenic IgA1 in patients with IgA nephropathy, offering a promising upstream thera
Breaking the Cystine Barrier: Long-term Safety and Efficacy of CTNS-RD-04 Gene Therapy in Cystinosis
A phase 1-2 trial shows that autologous hematopoietic stem-cell gene therapy (CTNS-RD-04) safely reduces lysosomal cystine levels in patients with cystinosis, potentially offering a definitive alternative to lifelong cysteamine therapy.
Selective TRPC6 Inhibition Emerges as a Novel Therapeutic Paradigm for Focal Segmental Glomerulosclerosis
A Phase 2 trial of BI 764198, a selective TRPC6 inhibitor, demonstrates significant proteinuria reduction in patients with focal segmental glomerulosclerosis. This study provides the first clinical evidence for podocyte-targeted therapy, ma
SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels
A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.
SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis
A meta-analysis of over 70,000 participants confirms that SGLT2 inhibitors significantly reduce chronic kidney disease progression regardless of baseline kidney function or albuminuria levels, supporting their use even in patients with Stag
Liberating the Kidney: Can a Conservative Dialysis Strategy Improve Recovery in AKI-D?
The LIBERATE-D randomized trial suggests that a conservative, indication-driven dialysis strategy may enhance kidney recovery and reduce treatment burden in stable patients with dialysis-requiring acute kidney injury compared to conventiona
Beyond the Plate: Mediterranean Lifestyle as a Potent Shield Against Chronic Kidney Disease
A large-scale prospective study from the UK Biobank reveals that a comprehensive Mediterranean lifestyle—integrating diet, physical activity, and social connectivity—significantly reduces the risk of incident chronic kidney disease by up to
Holistic Mediterranean Lifestyle Linked to 35 Percent Lower Risk of Incident Chronic Kidney Disease
A large-scale prospective study from the UK Biobank reveals that high adherence to a Mediterranean lifestyle, including diet, physical activity, and social habits, significantly reduces the risk of developing chronic kidney disease over an
Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes
A pilot study shows that combining GLP-1 analogues and SGLT2 inhibitors with lifestyle changes significantly reduces body weight and albuminuria in overweight Type 1 diabetes patients with CKD, though glycemic and blood pressure improvement
Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes
A randomized clinical study demonstrates that while SGLT2 inhibitors alone may induce urinary dysbiosis and increase pathogen risk, combining them with DPP-4 inhibitors restores a healthy urinary microbiota, potentially improving patient co
Precision Medicine Outperforms Standard Albuminuria Thresholds for SGLT2 Inhibitor Selection in Type 2 Diabetes
A new precision medicine model identifies high-benefit patients for SGLT2 inhibitor treatment even when albumin levels appear normal, potentially preventing 10% more kidney failure events than current guidelines that rely solely on albuminu
Beyond the Dialyzer: The Multidimensional Burden of Chronic Pain in Maintenance Hemodialysis Patients
A cross-sectional analysis of the HOPE Consortium Trial reveals that chronic pain in hemodialysis patients is widespread, frequently musculoskeletal and neuropathic, and strongly associated with psychological and sociodemographic factors ra
GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal
Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various st
Dapagliflozin Improves Vascular Stiffness and Cardiorenal Hemodynamics: New Insights from a Randomized Controlled Trial
A 12-week randomized trial demonstrates that dapagliflozin significantly reduces arterial stiffness and modulates fluid dynamics in patients at cardiovascular risk, regardless of diabetes status, providing a mechanistic basis for its broad
Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial
The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite k
SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial Emulation
A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.
Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial
A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without incre
Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF
A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline
Browse by specialty
Open language-specific specialty feeds and department pages.